Revolutionizing Cardiac Care: Ambiq and CardioMedive’s Cutting-Edge Edge AI Monitor

In a groundbreaking partnership, Ambiq and CardioMedive have joined forces to introduce Medive, a cutting-edge cardiac care platform powered by Ambiq’s ultra-low-power Apollo510 MCU. This innovative solution integrates a range of clinical-grade monitoring tools, including ECG, blood pressure, SpO₂, and advanced diagnostic modules like spirometry and thermal imaging. By leveraging edge AI technology, Medive enables real-time anomaly detection, patient alerts, and predictive insights, significantly reducing reliance on cloud-based systems.

Acknowledged for its groundbreaking advancements in remote cardiovascular monitoring, Medive was honored with the prestigious "Medical Innovation of the Year" award by the Romanian Healthcare Awards. Fumihide Esaka, CEO of Ambiq, expressed pride in contributing to this digital health innovation, emphasizing the platform’s role in enhancing prevention, diagnosis, and disease management through ultra-low power solutions. With a focus on improving accessibility to hospital-grade cardiac care across diverse environments, Medive is set to launch commercially in Europe and the U.K. in Q3 2026, with plans for expansion to the U.S., Canada, and the Asia-Pacific region in 2027.

This transformative partnership between Ambiq and CardioMedive signifies a significant leap forward in the realm of cardiac care, promising to revolutionize patient care experiences in both home and hospital settings. With its state-of-the-art technology and emphasis on accessibility, Medive is poised to make a lasting impact on the healthcare landscape, offering a comprehensive solution for effective prevention, diagnosis, and management of cardiovascular conditions.